Double-blind and long-term open-label studies have demonstrated a remark ably favorable safety profile for bevantolol. The drug was associated with a low incidence of adverse experiences similar to that observed with placebo. The adverse experiences were mostly mild to moderate and of the types found previ ously for other beta-blocking drugs. Very few patients withdrew from clinical studies because of adverse effects. Some patients continued on study for over four years. Bevantolol offers safe beta-blocking activity for the long-term treat ment of angina and hypertension.